Candriam Luxembourg S.C.A. cut its holdings in Exelixis, Inc. (NASDAQ:EXEL) by 6.9% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 202,000 shares of the biotechnology company’s stock after selling 15,000 shares during the quarter. Candriam Luxembourg S.C.A. owned 0.07% of Exelixis worth $4,894,000 as of its most recent SEC filing.
Several other institutional investors have also bought and sold shares of the stock. FMR LLC boosted its stake in shares of Exelixis by 2.0% in the second quarter. FMR LLC now owns 43,748,695 shares of the biotechnology company’s stock valued at $1,077,530,000 after buying an additional 857,452 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Exelixis by 7.2% in the second quarter. Vanguard Group Inc. now owns 25,441,964 shares of the biotechnology company’s stock valued at $626,635,000 after buying an additional 1,706,893 shares in the last quarter. Meditor Group Ltd boosted its stake in shares of Exelixis by 5.5% in the second quarter. Meditor Group Ltd now owns 20,229,713 shares of the biotechnology company’s stock valued at $498,258,000 after buying an additional 1,046,000 shares in the last quarter. Matrix Capital Management Company LP boosted its stake in shares of Exelixis by 8.8% in the second quarter. Matrix Capital Management Company LP now owns 15,117,460 shares of the biotechnology company’s stock valued at $372,343,000 after buying an additional 1,225,000 shares in the last quarter. Finally, Goldman Sachs Group Inc. boosted its position in Exelixis by 13.1% during the second quarter. Goldman Sachs Group Inc. now owns 7,059,232 shares of the biotechnology company’s stock worth $173,869,000 after purchasing an additional 818,782 shares in the last quarter. Hedge funds and other institutional investors own 78.06% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This story was first reported by Markets Daily and is the property of of Markets Daily. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this story can be viewed at https://www.themarketsdaily.com/2017/11/14/candriam-luxembourg-s-c-a-has-4-89-million-position-in-exelixis-inc-exel.html.
Exelixis, Inc. (NASDAQ EXEL) opened at $26.05 on Tuesday. Exelixis, Inc. has a 1-year low of $14.22 and a 1-year high of $32.50. The firm has a market capitalization of $7,710.00, a price-to-earnings ratio of 50.69, a PEG ratio of 1.25 and a beta of 1.89.
Exelixis (NASDAQ:EXEL) last released its quarterly earnings results on Wednesday, November 1st. The biotechnology company reported $0.26 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.08 by $0.18. Exelixis had a return on equity of 105.47% and a net margin of 36.80%. The company had revenue of $152.50 million during the quarter, compared to analysts’ expectations of $104.91 million. During the same period in the previous year, the firm posted ($0.04) earnings per share. The business’s revenue for the quarter was up 145.2% compared to the same quarter last year. research analysts anticipate that Exelixis, Inc. will post 0.45 EPS for the current fiscal year.
A number of analysts have commented on EXEL shares. TheStreet upgraded Exelixis from a “c” rating to a “b-” rating in a research report on Monday, August 7th. Piper Jaffray Companies reiterated a “buy” rating and set a $29.00 target price on shares of Exelixis in a research report on Thursday, August 3rd. BidaskClub downgraded Exelixis from a “strong-buy” rating to a “buy” rating in a research report on Monday, August 14th. Needham & Company LLC reiterated a “buy” rating and set a $30.00 target price (up from $28.00) on shares of Exelixis in a research report on Tuesday, September 12th. Finally, Zacks Investment Research upgraded Exelixis from a “hold” rating to a “buy” rating and set a $29.00 target price on the stock in a research report on Tuesday, October 10th. Six equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $31.38.
In other news, insider Michael Morrissey sold 300,000 shares of the business’s stock in a transaction on Thursday, September 14th. The stock was sold at an average price of $26.90, for a total value of $8,070,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Gisela Schwab sold 100,000 shares of the business’s stock in a transaction on Thursday, September 28th. The stock was sold at an average price of $23.79, for a total value of $2,379,000.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 970,152 shares of company stock valued at $25,923,457. Insiders own 5.10% of the company’s stock.
Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.
Want to see what other hedge funds are holding EXEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exelixis, Inc. (NASDAQ:EXEL).
Receive News & Ratings for Exelixis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.